Drug-induced respiratory disease in patients with hematological diseases.
Patients with hematological malignancies or recipients of hematopoietic stem cell transplants may develop myriad pulmonary manifestations, as a complication of either the disease or the diverse agents used to treat the disease. Clinical, radiographic, and physiological features of drug-induced and radiation-induced pulmonary injury are often difficult to distinguish from other causes of pulmonary infiltrates (e.g., infections, pulmonary edema, alveolar hemorrhage, etc.). Fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) is essential to exclude infectious etiologies. In some cases, surgical lung biopsies are required to establish a specific etiological diagnosis. This review discusses the myriad causes of lung injury/toxicity that may afflict patients with hematological malignancies or transplant recipients, and presents diagnostic and therapeutic approaches.
Camus
Philippe
P
Department of Pulmonary Medicine, Hopital Le Bocage, Dijon, France. philippe.camus@chu-dijon.fr
Costabel
Ulrich
U
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D001999:Bronchoscopy; D006402:Hematologic Diseases / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008171:Lung Diseases / Q000139:chemically induced* / Q000175:diagnosis; D011878:Radiotherapy / Q000009:adverse effects
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents